Although prior research suggests that heritability accounts for 66% to 85% of schizophrenia risk, additional risk factors include stress and the “nature of caregiving,” or the home environment and caregiver conduct.
Among participants socially isolated in childhood, 10% had 2 or more reported psychotic experiences compared with only 1% for non-socially isolated participants.
Adjunctive treatment with pimavanserin did not result in a statistically significant change from baseline in Positive and Negative Syndrome Scale (PANSS) total score in patients with schizophrenia.
People with schizophrenia and cognitive impairment reported significant childhood adversity, especially the lack of parental involvement and family hardships.
Generalized fractional anisotropy reductions in bundles connecting regions involved in mood regulation and motor function were seen in patients with schizophrenia and bipolar disorder.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to SEP-363856 (Sunovion), an investigational treatment for schizophrenia. SEP-363856 is believed to work by activating trace amine-associated receptor 1 (TAAR1) in addition to 5-HT1A receptors; unlike other antipsychotics, this novel agent does not bind to D2 or 5-HT2A receptors. The Breakthrough Therapy designation was…
